Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Connect Biopharma Holdings LtdCNTB · Entity 6516 | Director · Chief Executive Officer | March 16, 2026 | March 16, 2026 |
| HERON THERAPEUTICS, INC. /DE/HRTX · Entity 7133 | Director · Chief Executive Officer | January 18, 2023 | January 20, 2023 |
| Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954 | Director | August 19, 2026 | August 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Connect Biopharma Holdings Ltd
Report date March 16, 2026 · Filed March 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 95,147 |
Reported balance
Holding disclosure · report date 2026-03-16 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 95,147 |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Joint Account with Spouse | 128,887 |
Reported balance
Holding disclosure · report date 2026-03-16 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 128,887 |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.77 · Expires 2034-06-12 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-16 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F1: The stock option vests and becomes exercisable over four years, with 25% vesting on the first anniversary of the date of grant, and then with respect to the remaining shares on a ratable monthly basis over the next three years, subject to continuous service with the Company as of each applicable vesting date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.97 · Expires 2034-12-26 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-16 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F1: The stock option vests and becomes exercisable over four years, with 25% vesting on the first anniversary of the date of grant, and then with respect to the remaining shares on a ratable monthly basis over the next three years, subject to continuous service with the Company as of each applicable vesting date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.69 · Expires 2035-12-26 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-16 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F2: The stock option vests and becomes exercisable on a ratable monthly basis over four years, subject to continuous service with the Company as of each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable over four years, with 25% vesting on the first anniversary of the date of grant, and then with respect to the remaining shares on a ratable monthly basis over the next three years, subject to continuous service with the Company as of each applicable vesting date.
F2: The stock option vests and becomes exercisable on a ratable monthly basis over four years, subject to continuous service with the Company as of each applicable vesting date.
HERON THERAPEUTICS, INC. /DE/
Report date January 18, 2023 · Filed January 20, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.13 · Expires 2033-01-18 | Direct | 850,000 |
Reported balance
After 2023-01-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-18 · Grant · Acquired 850,000 · Balance 850,000 F1: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant.
Kiniksa Pharmaceuticals International, plc
Report date August 19, 2026 · Filed August 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary ShareSEC Table I · non-derivative | Direct | 12,745 |
Reported balance
After 2026-08-19 transaction · row 1
1 source rowRow 1 · 2026-08-19 · Gift · Disposed 2,600 · Balance 12,745 F1: This transaction involves a bona fide gift of securities from the reporting person to a donor advised fund. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction involves a bona fide gift of securities from the reporting person to a donor advised fund.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 13, 2020 Filed Oct 15, 2020 20:23 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantEmployee Stock Option (Right to Buy) · Derivative | 350,000 | $0.00 Strike: $15.72 | $0.00 |
DisclosureSEC source: 0001209191-20-054907 · doc4.xml · derivative · entry 2 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2030-10-13 F2 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:12 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 18,760 | $0.00 Strike: $25.48 | $0.00 |
DisclosureSEC source: 0001104659-20-080550 · a4.xml · derivative · entry 1 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,760 Underlying: Class A Common Shares · 18,760 shares Expires 2030-06-29 F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of grant. The date of grant is June 30, 2020. Read SEC document |
| April 30, 2020 Filed Oct 15, 2020 20:23 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | OtherCommon Stock | 1,158 | $12.12 | $14,036.12 |
DisclosureSEC source: 0001209191-20-054907 · doc4.xml · nonDerivative · entry 1 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,226 F1 · kind: Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2020. Read SEC document |
| December 27, 2019 Filed Feb 14, 2020 21:56 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GiftCommon Stock | 6,584 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-009728 · doc5.xml · nonDerivative · entry 1 Quart Barry D · CIK 0001384243 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,068 F1 · kind: Represents shares that were donated to a charity. Read SEC document |
| December 19, 2019 Filed Dec 23, 2019 21:29 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantEmployee Stock Option (Right to Buy) · Derivative | 325,000 | $0.00 Strike: $25.02 | $0.00 |
DisclosureSEC source: 0001209191-19-061798 · doc4.xml · derivative · entry 1 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,000 Underlying: Common Stock · 325,000 shares Expires 2029-12-19 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant. Read SEC document |
| October 03, 2019 Filed Oct 4, 2019 23:58 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | PurchaseCommon Stock | 4,571 | $17.50 | $79,992.50 |
DisclosureSEC source: 0001209191-19-052612 · doc4.xml · nonDerivative · entry 2 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,652 Read SEC document |
| May 29, 2019 Filed May 30, 2019 22:33 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 18,760 | $0.00 Strike: $15.47 | $0.00 |
DisclosureSEC source: 0001179110-19-006869 · edgar.xml · derivative · entry 1 Quart Barry D · CIK 0001384243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,760 Underlying: Class A Common Shares · 18,760 shares Expires 2029-05-28 F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of grant. The date of grant is May 29, 2019. Read SEC document |
| April 30, 2019 Filed Oct 4, 2019 23:58 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | OtherCommon Stock | 806 | $18.43 | $14,852.97 |
DisclosureSEC source: 0001209191-19-052612 · doc4.xml · nonDerivative · entry 1 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,081 F1 · kind: Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2019. Read SEC document |
| December 15, 2018 Filed Dec 19, 2018 01:09 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantEmployee Stock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $24.97 | $0.00 |
DisclosureSEC source: 0001209191-18-063351 · doc4.xml · derivative · entry 1 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2028-12-15 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the Date of Grant. Read SEC document |
| September 14, 2018 Filed Sep 14, 2018 15:41 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 19,675 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001209191-18-050997 · doc4.xml · derivative · entry 2 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 710,601 Underlying: Common Stock · 19,675 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Cash exercise and hold. F2 · derivative.exercise_date: At the date of filing, 523,101 shares of the options granted pursuant to the underlying awards were fully vested and exercisable. Read SEC document |
| September 14, 2018 Filed Sep 14, 2018 15:41 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 19,675 | $7.20 | $141,660.00 |
DisclosureSEC source: 0001209191-18-050997 · doc4.xml · nonDerivative · entry 1 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,275 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Cash exercise and hold. Read SEC document |
| June 21, 2018 Filed Jun 23, 2018 01:35 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001209191-18-039348 · doc4.xml · derivative · entry 4 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 50,000 shares Expires 2024-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed in December 2017. F3 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant (12/12/2014). Read SEC document |
| June 21, 2018 Filed Jun 23, 2018 01:35 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | SaleCommon Stock | 50,000 | $39.05 | $1,952,500.00 |
DisclosureSEC source: 0001209191-18-039348 · doc4.xml · nonDerivative · entry 3 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,600 F2 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed in December 2017. Read SEC document |
| June 21, 2018 Filed Jun 23, 2018 01:35 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 50,000 | $9.05 | $452,500.00 |
DisclosureSEC source: 0001209191-18-039348 · doc4.xml · nonDerivative · entry 2 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed in December 2017. Read SEC document |
| April 30, 2018 Filed Jun 23, 2018 01:35 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | OtherCommon Stock | 1,607 | $13.22 | $21,240.52 |
DisclosureSEC source: 0001209191-18-039348 · doc4.xml · nonDerivative · entry 1 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,600 F1 · kind: Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2018. Read SEC document |
| March 19, 2018 Filed Mar 19, 2018 23:22 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001209191-18-020736 · doc4.xml · derivative · entry 3 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 730,276 Underlying: Common Stock · 100,000 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed in December 2017. F2 · derivative.exercise_date: At the date of filing, 542,776 shares of the options granted pursuant to the underlying awards were fully vested and exercisable. Read SEC document |
| March 19, 2018 Filed Mar 19, 2018 23:22 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | SaleCommon Stock | 100,000 | $29.75 | $2,975,000.00 |
DisclosureSEC source: 0001209191-18-020736 · doc4.xml · nonDerivative · entry 2 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,993 F1 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed in December 2017. Read SEC document |
| March 19, 2018 Filed Mar 19, 2018 23:22 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 100,000 | $7.20 | $720,000.00 |
DisclosureSEC source: 0001209191-18-020736 · doc4.xml · nonDerivative · entry 1 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,993 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed in December 2017. Read SEC document |
| March 14, 2018 Filed Mar 17, 2018 01:00 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionEmployee Stock Option(Right to Buy) · Derivative | 100,000 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0000899243-18-007825 · doc4.xml · derivative · entry 3 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 830,276 Underlying: Common Stock · 100,000 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed in December 2017. F2 · derivative.exercise_date: At the date of filing, 642,776 shares of the options granted pursuant to the underlying awards were fully vested and exercisable. Read SEC document |
| March 14, 2018 Filed Mar 17, 2018 01:00 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | SaleCommon Stock | 100,000 | $24.75 | $2,475,000.00 |
DisclosureSEC source: 0000899243-18-007825 · doc4.xml · nonDerivative · entry 2 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,993 F1 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed in December 2017. Read SEC document |
| March 14, 2018 Filed Mar 17, 2018 01:00 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 100,000 | $7.20 | $720,000.00 |
DisclosureSEC source: 0000899243-18-007825 · doc4.xml · nonDerivative · entry 1 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,993 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed in December 2017. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 21:15 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantEmployee Stock Option (Right to Buy) · Derivative | 310,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-17-066627 · doc4.xml · derivative · entry 2 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,000 Underlying: Common Stock · 310,000 shares Expires 2027-12-18 F2 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the Date of Grant. Read SEC document |
| April 28, 2017 Filed Dec 20, 2017 21:15 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | OtherCommon Stock | 1,684 | $12.62 | $21,256.29 |
DisclosureSEC source: 0001209191-17-066627 · doc4.xml · nonDerivative · entry 1 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,993 F1 · kind: Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 28,2017. Read SEC document |
| December 21, 2016 Filed Dec 23, 2016 21:04 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantEmployee Stock Option (Right to Buy) · Derivative | 310,000 | $0.00 Strike: $13.00 | $0.00 |
DisclosureSEC source: 0001209191-16-156661 · doc4.xml · derivative · entry 1 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,000 Underlying: Common Stock · 310,000 shares Expires 2026-12-21 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant. Read SEC document |
| November 04, 2016 Filed Apr 15, 2021 20:54 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GiftCommon Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-026844 · doc4.xml · nonDerivative · entry 3 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,509 F2 · shares: Represents transfer of shares by the reporting person's spouse to an account jointly held by the reporting person. The shares were inadvertently omitted from prior Form 5 filings. Read SEC document |
| November 04, 2016 Filed Apr 15, 2021 20:54 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GiftCommon Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-026844 · doc4.xml · nonDerivative · entry 2 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 0 F2 · shares: Represents transfer of shares by the reporting person's spouse to an account jointly held by the reporting person. The shares were inadvertently omitted from prior Form 5 filings. Read SEC document |
| June 20, 2015 Filed Apr 15, 2021 20:54 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | OtherCommon Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-026844 · doc4.xml · nonDerivative · entry 1 Quart Barry D · CIK 0001384243 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 600 F1 · shares: The reporting person acquired indirect ownership of the shares upon marriage to the reporting person's spouse on June 20, 2015. The shares were inadvertently omitted from prior Form 4 filings. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.